CJC-1295 / Ipamorelin Dosage: Blend Math & Evidence [2026]

This guide examines CJC-1295/ipamorelin dosing claims, 5mg/5mg blend calculations, preparation, timing, cycling and lab monitoring. It separates what human research shows from protocol assumptions. Accurate vial arithmetic does not establish an effective or appropriate treatment regimen.

Peptide Dossier Editorial Team · Updated September 8, 2026. Editorial evidence review; not a clinician-reviewed treatment protocol.

Understanding the CJC-1295 / Ipamorelin Stack

CJC-1295 is a GHRH analog; ipamorelin is a growth hormone secretagogue studied through a different receptor pathway. Raun and colleagues’ original ipamorelin work was preclinical, including animal experiments. That mechanistic rationale does not establish the size of a combination benefit in people.

A vial labeled 5mg/5mg states 5 milligrams of each ingredient, not 5 milligrams combined. That label alone does not establish the exact CJC formulation, storage conditions or shelf life. Confirm the formulation and product-specific instructions before using any volume calculation below.

Human evidence: Teichman and colleagues’ short randomized trials studied long-acting CJC-1295 in healthy adults, finding GH and IGF-I increases and an estimated 5.8-8.1 day half-life. They did not study this daily blend or establish an athletic benefit. Do not assume a product labeled “without DAC” is interchangeable with the long-acting compound studied, or that stimulating endogenous hormones guarantees no suppression or rapid recovery.

Vial Reconstitution: The 5mg/5mg Standard

The example here uses a vial labeled 5mg CJC-1295 + 5mg ipamorelin: 10mg combined. Other ingredient ratios or concentrations require a different calculation.

Preparation checks and an arithmetic example:

1. Confirm the diluent: Bacteriostatic water is water with a preservative, not 0.9% saline. Water and saline are not interchangeable by name. Follow the exact product or dispensing pharmacy instructions. See the bacteriostatic water label.
2. Confirm preparation details: Use the specified diluent volume, supplies and handling instructions. If these are missing, obtain them rather than treating this example as a mixing recipe.
3. Keep the quantities distinct: Diluent added and final solution volume are not automatically identical. Concentration calculations use the final solution volume.
4. Example final concentration: A stated 5mg + 5mg blend at a final solution volume of 1.0mL has 10mg/mL total concentration. This example does not verify the contents of a vial.
5. Break down by peptide: Each peptide is 5mg/mL individually. So 0.1mL (10 U-100 units) = 1000mcg total = 500mcg CJC-1295 + 500mcg Ipamorelin. This conversion does not establish an appropriate dose.
6. Storage and discard: Follow formulation-specific temperature and discard instructions. Refrigeration alone does not establish 8-10 weeks of stability or sterility. Other peptide products can have very different limits: EGRIFTA SV labeling, for example, requires immediate use after mixing. Its instructions are not a recipe for this blend.

Dosing Math Made Simple: On a U-100 syringe, 100 units represents 1mL; graduation spacing varies by syringe. For this example only, with 5mg/mL of each ingredient:

• 2 U-100 units (0.02mL) = 100mcg per peptide (200mcg total)
• 4 U-100 units (0.04mL) = 200mcg per peptide (400mcg total)
• 6 U-100 units (0.06mL) = 300mcg per peptide (600mcg total)

Syringe units describe volume, not the amount of each ingredient. Check the actual syringe graduations and written product instructions; a correct conversion is not a substitute for preparation or injection training.

Dosing Protocols: What the Numbers Mean

“Beginner,” “intermediate” and “advanced” are not validated dose categories in the studies cited here. The following quantities are retained as calculation examples, not a recommendation to start, escalate or cycle the blend. Each assumes 5mg of each ingredient in a final 1mL solution.

• 100mcg of each ingredient: 0.02mL, equivalent to 2 U-100 units; 200mcg combined.
• 200mcg of each ingredient: 0.04mL, equivalent to 4 U-100 units; 400mcg combined.
• 300mcg of each ingredient: 0.06mL, equivalent to 6 U-100 units; 600mcg combined.

Supply arithmetic: Total ingredient mass equals the amount per administration multiplied by the number of administrations. For example, 100mcg of each ingredient on 56 occasions totals 5.6mg of each ingredient, requiring two whole 5mg/5mg vials by mass alone. That does not establish a 56-day treatment course or usable shelf life; wastage and product-specific discard limits can increase the quantity needed.

The evidence reviewed here does not support assigning 2-4, 4-8 or 8-12 pounds of lean-muscle gain to those dose tiers. Increasing a number in the calculation does not demonstrate increasing clinical benefit.

Injection Timing and Frequency: Evidence and Practice

Bedtime, morning-plus-bedtime and multiple-daily schedules are protocol proposals, not interchangeable schedules validated by the cited CJC study. A theory about aligning with natural GH pulses is different from evidence that a particular schedule improves sleep, strength or body composition.

The sources reviewed here do not substantiate the earlier claim that one or two daily injections deliver 80-90% of a maximum response. There is also no basis here for advising additional injections simply to make a protocol more “advanced.”

Emerging discussion: Andrew Huberman discusses GH-related peptides and formulation distinctions in his peptide therapeutics episode. This is expert commentary, not a controlled blend trial or a dosing prescription. Commentary can help identify questions to investigate without settling the regimen.

Cycling Schedules: What Is and Is Not Established

The 12-16 week courses and 4-8 week breaks previously described here are not validated as a standard blend protocol by the sources reviewed. Neither a scheduled break nor a lower-dose “bridge” has been established here to reset receptors, prevent tolerance or make ongoing use safe.

Similarly, the reviewed evidence does not establish a universal loss of response at week 8-10 or a guarantee that most benefit occurs by week 12. Duration, reassessment and any decision to stop require an individualized clinical discussion rather than a calendar labeled “standard.”

Lab Monitoring: IGF-1 and Other Markers

Lab results can inform clinical assessment; they do not independently establish an appropriate blend dose. Labcorp’s IGF-1 test documentation describes age- and sex-adjusted reference intervals, differences between assays and the need to interpret results alongside other clinical information. A higher IGF-1 number is not automatically a better outcome.

Baseline discussion:

• Review the reason for testing, medical history, symptoms and the exact product with the treating clinician.
• Ask whether IGF-1 and assessment of glucose control or lipids would be useful in that clinical context; this is not a mandatory panel for every reader.
• Keep the original report, including its reference interval and assay, for comparison. Report medicines and supplements to the clinician and laboratory.

Follow-up testing:

• IGF-1: Compare with the appropriate laboratory interval and prior results, not a universal performance target.
• Glucose and lipids: Discuss changes with the clinician rather than automatically changing the peptide dose from one number.
• Timing: Agree on when to repeat testing and when symptoms warrant earlier assessment; a fixed week 6-8 schedule is not established for every formulation and patient.

After stopping:

• Follow-up timing depends on the formulation, findings and clinical situation. A single result two weeks later does not certify complete endocrine recovery.

Interpreting Results:

• There is no universal “optimal” 200-350 ng/mL blend target established by the sources reviewed here.
• An IGF-1 result above 400 ng/mL does not by itself show a good response. A result of 150-200 ng/mL does not justify an automatic 50-100mcg increase.
• Abnormal results need clinical interpretation; neither an isolated IGF-1 cutoff nor a glucose cutoff supplies a self-titration rule.

Side Effects: What to Watch For

The short CJC-1295 trials cited above reported no serious adverse reactions, but they cannot establish reliable rates for long-term daily combination use. “Minimal side effects” and blanket claims of no liver or cardiovascular harm go beyond that evidence.

• Joint aches, swelling or tingling: New symptoms are reasons to contact the treating clinician, not evidence that GH is “working.”
• Appetite or weight changes: Record what changed and when; the change alone does not establish a benefit or identify its cause.
• Injection-site symptoms: Worsening pain, redness or swelling merits assessment rather than being assumed harmless.
• Severe reactions: Breathing difficulty or swelling of the face or throat calls for urgent medical care.

A statement that a symptom is “rare below 200mcg” needs data for that formulation and dose. Those data are not established by the sources cited here. Nor can a non-androgenic mechanism prove that a product has no effect on other hormones or organs.

What to Expect: Assessing Changes Over Time

Interest in this stack includes sleep, exercise recovery, muscle gain and body composition. The cited studies do not establish a week-by-week improvement timeline for the blend. A hormone change is a biological finding, not proof of better health, performance or quality of life.

• Sleep and recovery: If tracking these, use consistent measures and record changes in training, nutrition and other treatments that could explain improvement.
• Body composition: Scale weight alone cannot distinguish muscle gain from fluid or fat changes.
• Strength and well-being: An individual experience can be worth discussing without being treated as a result everyone should expect.
• Lab changes: Interpret them with the laboratory reference interval and clinical context described above, not as a performance score.

Evidence levels: Human research, preclinical findings and expert commentary are identified separately in this guide. Personal experiences may generate useful hypotheses; they do not establish a dose-response curve or a predictable benefit timeline.

Correction record, September 8, 2026: corrected diluent identity and product-independent storage claims; qualified dosing, timing and cycling assertions; replaced fixed IGF-1 self-titration rules and unsupported benefit/safety promises. Existing per-ingredient arithmetic and section links are retained.